Merck Nears Acquisition of Cidara Therapeutics at Significant Premium 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Obamacare Premiums Set to Double in 2026 as Subsidy Expiration Looms Amid U.S. Shutdown 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
U.S. Reveals 2026 Medicare Star Ratings: Aetna, UnitedHealth Lead in Quality Scores 
Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition 
Novo Nordisk and Eli Lilly Lower Prices for Weight-Loss Drugs Amid U.S. Agreement 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
Trump Backs Review of U.S. Childhood Vaccine Schedule After Hepatitis B Policy Change 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Johnson & Johnson is reportedly exploring the acquisition of biopharmaceutical company Intra-Cellular Therapies, according to Bloomberg News. The potential deal, valued at approximately $10 billion, could be finalized as early as this week, though discussions remain in early stages.
Intra-Cellular Therapies is renowned for Caplyta, its FDA-approved treatment for schizophrenia and bipolar disorders. Acquiring the company would bolster J&J’s neuroscience portfolio, helping mitigate revenue declines expected from upcoming patent expirations on its blockbuster drugs.
Despite the promising prospects, sources caution that negotiations may not result in a finalized agreement. Intra-Cellular’s stock surged nearly 15% last Friday, reflecting heightened investor optimism over the potential acquisition.
J&J continues to focus on high-growth therapeutic areas to strengthen its pharmaceutical division amidst growing market competition. If successful, this acquisition would align with the company's strategy to expand its innovative treatments and sustain long-term growth.
